US equities
|
SPCX
$171.09
▲+0.00%
META
$741.90
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
AMZN
$251.40
▲+0.00%
AMD
$631.75
▲+0.00%
SNDK
$1,704.16
▲+0.00%
TSLA
$378.73
▲+0.00%
SPCX
$171.09
▲+0.00%
META
$741.90
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
AMZN
$251.40
▲+0.00%
AMD
$631.75
▲+0.00%
SNDK
$1,704.16
▲+0.00%
TSLA
$378.73
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Oncotelic Therapeutcs Inc
(OP:
OTLC
)
0.0217
UNCHANGED
Delayed Quote
Updated: 3:59 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncotelic Therapeutcs Inc
< Previous
1
2
3
4
5
6
7
Next >
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation
November 21, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Preliminary $1.7B Pipeline Valuation From Joint Venture Partner
November 20, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Intellectual Property
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
November 20, 2025
Via
Investor Brand Network
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
November 20, 2025
From
BioMedWire
Via
GlobeNewswire
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
November 20, 2025
Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platform
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
November 11, 2025
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy
November 07, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium
November 03, 2025
Via
Investor Brand Network
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium
October 31, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances
October 30, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
October 30, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology
October 28, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies
October 28, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
Via
Investor Brand Network
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium
October 23, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery
October 21, 2025
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies
October 17, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
October 08, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia
October 08, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
October 08, 2025
Using Sapu Nano’s proprietary Deciparticle™ technology, Sapu-003 delivers everolimus intravenously
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment
October 01, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer
September 24, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
September 24, 2025
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast
September 22, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum
September 19, 2025
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
September 19, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research
September 18, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
